CIRM Funded Clinical Trials

Genetic Re-programming of Stem Cells to Fight Cancer

Disease Area:
CIRM Grant:
DR2A-05309 (Closed)
Award Value:
Trial Stage:
Phase 1
Trial Status:
Targeted Enrollment:
5 ID:


There are few options for patients whose cancers have metastasized due to resistance to current therapies. This team is using gene editing technology to modify a patient’s own immune system cells and blood-forming stem cells with the aim of creating a continuous supply of immune cells that can recognize and attack hard-to-treat cancers.


Single dose. 


Primary: Safety and feasibility. Secondary: Persistence of gene-marked anti-cancer immune cells

News about this clinical trial:

Contact Trial Sponsor

CIRM Clinical Trial Resources

Patient Stories of Hope

CIRM Alpha Stem Cell Clinics

Patient Toolbox

Video on Stem Cell Trials

Other Resources

ISSCR Patient Website